
About Atantares
Atantares is a Healthcare company based in Cambridge (United States) founded in 2020 by Xin Zhao, Aniruddh Sarkar, and Kumaran Kolandaivelu. Atantares has raised $13.99 million across 3 funding rounds from investors including Qiming Venture Partners, Alibaba Health and Frees Fund. Its chief executive, as recorded, is Xin Zhao. Its focus areas include Life Sciences, Hematology, In Vitro Diagnostics Tests and Coagulopathies. Its competitors include Guardant Health, Foundation Medicine and ArcherDX; 3 of its 3 listed competitors have raised funding.
Company details
Developer of precision medicines smart diagnostic devices by fusing biochip and AI technologies. The company has developed a coagulation device that helps in monitoring specific drugs or blood products. It uses coagulation assays that monitor platelet function tests, clotting times, and viscoelasticity with a proprietary biochip platform. It provides a chimeric antigen receptor that helps in the treatment of hematological tumors, cardiac diseases, neurological disorders, and cancer. It uses an ultrasensitive immunoassay platform that provides cytokine profile data for managing CAR T-cell therapy and CRS mitigation.
- Headquarters Cambridge, United States
- Founders Xin Zhao, Aniruddh Sarkar, Kumaran Kolandaivelu
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Website atantares.com
- Social LinkedIn
- Total Equity Funding$13.99M (USD)
in 3 rounds
- Latest Funding Round$13.99M (USD), Seed
Jul 2023
- InvestorsQiming Venture Partners
& 6 more
Funding Insights of Atantares
Atantares has successfully raised a total of $13.99M across 3 strategic funding rounds. The most recent funding activity was a Seed round of $13.99 million completed in July 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $13.99M
- Total Rounds 3
- Last Round Seed β $13.99M
- First Round $150,000
(Feb 2020)
- Investors Count 7
All 3 funding rounds of Atantares with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2023 | $13.99M | Seed | β | Asia Green Fund | |
| Jul 2020 | $449,968 | Grant | β | β | |
| Feb 2020 | $150,000 | Grant | β | β |
7 investors in total: 7 institutional.
Investors in Atantares
Atantares has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Qiming Venture Partners, Alibaba Health and Frees Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Tech focused VC firm investing in early stage companies in the US & China | freesvc.com | Beijing, China | ||
Venture capital investments are directed toward multiple sectors. | 2006 | qimingvc.com | Shanghai, China | |
| asiagreenfund.com | ||||
Investment fund focused on biopharmaceutical innovation and growth. | 2020 | fosunhealthcapital.com | Shanghai, China | |
| jiachengcap.com | ||||
Online platform for pharmacy, consultations, and appointments is operated. | 1998 | alihealth.cn | Beijing, China | |
A government-backed foundation providing seed-stage investments to support small businesses. | 1950 | nsf.gov | Arlington, United States |
Investor details for Atantares
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Atantares
4 people are tracked at Atantares (4 in leadership).
| Name | Role | Group |
|---|---|---|
Xin Zhao | Founder & CEO | Leadership |
Aniruddh Sarkar | Co-Founder | Leadership |
Kumaran Kolandaivelu | Co-Founder | Leadership |
Dan Wu | Chief Technology Officer | Leadership |
Complete people profiles for Atantares
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Atantares
3 dated milestones of Atantares across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Atantares is founded.
- Funding First funding round of $150K.
- Funding Latest funding round, Seed, of $14.0M.
Competitors of Atantares
Atantares has 3 listed competitors in our database, 3 of them funded. They include Guardant Health, Foundation Medicine and ArcherDX.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| guardanthealth.com | 2012 | Redwood, United States | $557.5M | 1,351 | Digital sequencing technology for cancer detection is developed. | |
| foundationmedicine.com | 2010 | Cambridge, United States | $96.5M | 1,707 | Genomics-based diagnostic tests for cancer are provided. | |
| archerdx.com | 2013 | Boulder, United States | $152.6M | 429 | Molecular cancer diagnostic products are developed using patented AMP technology. |
Detailed competitors of Atantares
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Atantares (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Atantares
Complete news archive for Atantares
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Atantares
Atantares was founded in 2020.
Atantares is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Xin Zhao is the CEO of Atantares, as recorded in our data. They have also founded this company.
Atantares is a funded company, having raised a total of $13.99M across 3 funding rounds to date. The company's 1st funding round was a Grant of $150K, raised on Feb 2020.
Developer of precision medicines smart diagnostic devices by fusing biochip and AI technologies. The company has developed a coagulation device that helps in monitoring specific drugs or blood products. It uses coagulation assays that monitor platelet function tests, clotting times, and viscoelasticity with a proprietary biochip platform. It provides a chimeric antigen receptor that helps in the treatment of hematological tumors, cardiac diseases, neurological disorders, and cancer. It uses an ultrasensitive immunoassay platform that provides cytokine profile data for managing CAR T-cell therapy and CRS mitigation.
Atantares's top competitors include Guardant Health, Foundation Medicine and ArcherDX.
Atantares has 7 investors. Key investors include Qiming Venture Partners, Alibaba Health, Frees Fund, Asia Green Fund, and Fosun Health Capital.
